Florida Health Daily
SEE OTHER BRANDS

Your best source on healthcare and wellness news from Florida

Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

Press releases published on April 29, 2025

Apyx Medical Corporation Announces Two Peer-Reviewed Publications on the Use of Renuvion in Abdominal Body Contouring Procedures

Apyx Medical Corporation Announces Two Peer-Reviewed Publications on the Use of Renuvion in Abdominal Body Contouring Procedures

Two studies report favorable clinical outcomes and safety data for Renuvion® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin Rapid weight loss due to GLP-1 drugs expected to drive growth in patients …

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

BRISBANE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its …

Kestra Showcases Real-World Outcomes for ASSURE WCD at Heart Rhythm 2025

Kestra Showcases Real-World Outcomes for ASSURE WCD at Heart Rhythm 2025

KIRKLAND, Wash., April 29, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) (“Kestra”), a wearable medical device and digital healthcare company, today announced the presentation of new real-world data on the ASSURE® Wearable …

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Annovis Bio Appoints Hui Liu as Director of Biostatistics

MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) …

Incyclix Bio Granted U.S. FDA Fast Track Designation for INX-315 to Treat CCNE1-Amplified Platinum-Resistant/Refractory Ovarian Cancer

Incyclix Bio Granted U.S. FDA Fast Track Designation for INX-315 to Treat CCNE1-Amplified Platinum-Resistant/Refractory Ovarian Cancer

RESEARCH TRIANGLE PARK, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today …

Integer to Present at Bank of America Securities Health Care Conference on May 14

Integer to Present at Bank of America Securities Health Care Conference on May 14

PLANO, Texas, April 29, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced participation in the 2025 Bank of America Securities Health …

iCAD Collaborates with Microsoft to provide access to its Mammography Solutions in Microsoft’s Precision Imaging Network (PIN)

iCAD Collaborates with Microsoft to provide access to its Mammography Solutions in Microsoft’s Precision Imaging Network (PIN)

NASHUA, N.H., April 29, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, announced today a collaboration with Microsoft, to include a set of AI-powered …

Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting

Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting

CHARLESTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial …

Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD

Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD

Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., April 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company …

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long …

Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF)

Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF)

WATERTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …

Commure and HealthTap Partner to Deliver Seamless, Unified Virtual and In-Person Care

Commure and HealthTap Partner to Deliver Seamless, Unified Virtual and In-Person Care

SAN FRANCISCO, April 29, 2025 (GLOBE NEWSWIRE) -- Commure, a leader in health technology infrastructure, today announced a strategic partnership with virtual care innovator HealthTap to launch a unified healthcare solution that bridges the gap between in- …

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase …

Nautilus Biotechnology Reports First Quarter 2025 Financial Results

Nautilus Biotechnology Reports First Quarter 2025 Financial Results

SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2025. “In Q1, …

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …

OneMedNet’s regulatory-grade imaging Real-World Data (iRWD) now available in HealthVerity Marketplace™

OneMedNet’s regulatory-grade imaging Real-World Data (iRWD) now available in HealthVerity Marketplace™

MINNEAPOLIS, April 29, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), the leading provider of regulatory-grade imaging Real-World Data (iRWD), today announced that its iRWD solution is now available in HealthVerity Marketplace™, enabling …

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that it will present new clinical …

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced six …

Immutep Quarterly Activities Report Q3 FY25

Immutep Quarterly Activities Report Q3 FY25

Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestone Pivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC) 2025 Patient enrolment completed for the EFTISARC-NEO …

Reviva to Participate in the Citizens Life Sciences Conference

Reviva to Participate in the Citizens Life Sciences Conference

CUPERTINO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service